AD04
Alcohol Use Disorder (AUD) in genetically targeted patients
Phase 3Active; ONWARD Phase 3 trial completed, evaluating regulatory path forward.
Key Facts
Indication
Alcohol Use Disorder (AUD) in genetically targeted patients
Phase
Phase 3
Status
Active; ONWARD Phase 3 trial completed, evaluating regulatory path forward.
Company
About Adial Pharmaceuticals
Adial Pharmaceuticals is focused on the treatment and prevention of addictions and related disorders through a science-driven, genetically targeted approach. Its lead investigational drug, AD04, is a serotonin-3 receptor antagonist being developed for Alcohol Use Disorder in patients with specific genotypes, supported by a proprietary companion diagnostic. The company, founded in 2010 and listed on NASDAQ in 2018, is navigating late-stage clinical development and has recently signed a significant collaboration framework for Europe. Adial's mission is to build a leading pharmaceutical company improving the quality of life for patients suffering from addiction.
View full company profile